Zio ECG Utilization Software (ZEUS) System

The Zio ECG Utilization Software (ZEUS) System is a software medical device intended to analyze long-term continuous ECG data from compatible monitors, using automated algorithms and review by Certified Cardiographic Technicians to produce reports aiding clinicians in diagnosing cardiac arrhythmias in adult patients. This iteration introduces ECG segment detection, including QT analysis, to enhance its analytical capabilities for non-critical care ambulatory monitoring.

The Zio ECG Utilization Software (ZEUS) System is a software platform designed to capture, analyze, and report symptomatic and asymptomatic cardiac events using continuous electrocardiogram (ECG) information from compatible single-patient-use monitoring devices. Indicated for patients 18 years or older who are not in critical care, the system processes ECG data to generate a final report detailing beat-to-beat information, including ectopic runs, ECG segments, rhythms, and heart rate measurements. This report is intended for review by clinicians to aid in arrhythmia diagnosis and management. The ECG analysis component of the ZEUS System is utilized by Certified Cardiographic Technicians (CCTs) who review the results from an automated ECG analysis platform before the final report is published and made available via a secure website. The ZEUS System, as part of the broader Zio Service, supports the Zio AT service by automatically detecting clinically actionable arrhythmias and managing various data transmissions. A key technological update in this version is the introduction of ECG segment detection, specifically including QT segment analysis, alongside its existing rhythm detection algorithms (ECGDL and ECGML). While no new clinical testing was performed for this update, nonclinical verification and performance testing confirmed that the device meets its design requirements and intended use, focusing on the safety and effectiveness of these modifications compared to its predicate.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the introduction of 'ECG segment detection', specifically QT analysis, improve the diagnostic yield or clinical decision-making compared to the predicate device which lacked this feature?; What are the specific performance characteristics (e.g., sensitivity, specificity, positive predictive value) of the ECGDL and ECGML algorithms for detecting various types of arrhythmias and ECG segments?; What is the defined process and criteria used by Certified Cardiographic Technicians (CCTs) to review and curate the reports generated by the automated ECG analysis platform?; Can the ZEUS System integrate with cardiac monitoring devices other than those specified (Zio XT Patch, Zio AT Patch, Zio Monitor), and how does data input from different devices affect analysis consistency?; How does the ZEUS System differentiate and prioritize 'clinically actionable arrhythmia' for the Zio AT service compared to other detected cardiac events, and what are the notification pathways for these actionable events?